Walking the CER Path.

Abstract

Evidence-based medicine has been a rallying cry for payers, but an inability to define value, conflicting clinical trial designs, physician practice variations, and payment incentives confound efforts to make EBM go mainstream. CER may give EBM some legs - just as the biologics pipeline is about to overflow.

Cite this paper

@article{Adams2009WalkingTC, title={Walking the CER Path.}, author={Katherine T Adams}, journal={Biotechnology healthcare}, year={2009}, volume={6 3}, pages={12-24} }